These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38739017)

  • 1. Oncology drug pricing: potential Medicare savings on cancer-directed and supportive care medications through the Mark Cuban cost plus drug model.
    Bouvette MJ; Lam AB; Bouvette C; Ayanambakkam A; Nipp RD
    Oncologist; 2024 Jul; 29(7):e918-e921. PubMed ID: 38739017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
    Cortese BD; Dusetzina SB; Luckenbaugh AN; Al Hussein Al Awamlh B; Stimson CJ; Barocas DA; Penson DF; Chang SS; Talwar R
    J Clin Oncol; 2023 Oct; 41(29):4664-4668. PubMed ID: 37290029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Potential Urologic Prescription Drug Savings With Mark Cuban Cost Plus Drug Company.
    Schloegel V; Harris L; Harris A; Dropkin B
    Urol Pract; 2024 Mar; 11(2):276-282. PubMed ID: 38377158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Cost Savings in Medicare Part D Across Gastroenterology: An Assessment of Alternative Drug Sourcing.
    Bouvette CA; Bouvette M; Yohannan B; Rumman A; Ali I
    Am J Gastroenterol; 2024 Apr; 119(4):764-767. PubMed ID: 38084855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
    Raimond VC; Feldman WB; Rome BN; Kesselheim AS
    Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA; Woodward MA; Niziol LM; Lee PP; De Lott LB
    Ophthalmology; 2018 Mar; 125(3):332-339. PubMed ID: 28625684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Medicare Part D Savings on Generic Drugs From the Mark Cuban Cost Plus Drug Company.
    Lalani HS; Kesselheim AS; Rome BN
    Ann Intern Med; 2022 Jul; 175(7):1053-1055. PubMed ID: 35724381
    [No Abstract]   [Full Text] [Related]  

  • 8. Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model.
    Narendrula A; Lang J; Mossialos E
    Front Pharmacol; 2023; 14():1179253. PubMed ID: 37727389
    [No Abstract]   [Full Text] [Related]  

  • 9. Online Tools to Decrease Out-of-Pocket Prescription Costs for Patients: A Practical Guide for Urologists.
    Pockros B; Cortese BD; Michel K; Ellis TA; Talwar R
    Urol Pract; 2024 May; 11(3):454-460. PubMed ID: 38640418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
    Socal MP; Bai G; Anderson GF
    JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Medicare could get better prices on prescription drugs.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
    Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
    JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring economic impact of applying daily average consumption limits.
    Flavin BM; Nishida LM; Karbowicz SH; Renner ME; Leonard RJ
    J Manag Care Pharm; 2014 Feb; 20(2):159-64. PubMed ID: 24456317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Policy Recommendations for Public Health Plans to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
    Daniel H; Bornstein SS;
    Ann Intern Med; 2019 Dec; 171(11):825-827. PubMed ID: 31711137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.